Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 138

2.

Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis.

Gallardo A, Garcia-Valdecasas B, Murata P, Teran R, Lopez L, Barnadas A, Lerma E.

Breast Cancer Res Treat. 2017 Sep 1. doi: 10.1007/s10549-017-4486-z. [Epub ahead of print]

PMID:
28865009
3.

Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.

Martín M, Chacón JI, Antón A, Plazaola A, García-Martínez E, Seguí MA, Sánchez-Rovira P, Palacios J, Calvo L, Esteban C, Espinosa E, Barnadas A, Batista N, Guerrero A, Muñoz M, Romio E, Rodríguez-Martín C, Caballero R, Casas MI, Rojo F, Carrasco E, Antolín S.

Oncologist. 2017 Nov;22(11):1301-1308. doi: 10.1634/theoncologist.2017-0052. Epub 2017 Jul 12.

PMID:
28701571
4.

SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients.

Arqueros C, Salazar J, Arranz MJ, Sebio A, Mora J, Sullivan I, Tobeña M, Martín-Richard M, Barnadas A, Baiget M, Páez D.

Med Oncol. 2017 Aug;34(8):136. doi: 10.1007/s12032-017-0993-3. Epub 2017 Jul 7.

PMID:
28687963
5.

KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.

Sullivan I, Salazar J, Arqueros C, Andrés M, Sebio A, Majem M, Szafranska J, Martínez E, Páez D, López-Pousa A, Baiget M, Barnadas A.

Clin Transl Oncol. 2017 Jul;19(7):884-890. doi: 10.1007/s12094-017-1620-7. Epub 2017 Feb 1.

PMID:
28150169
6.

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).

González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortés J, de la Haba J, López-Vega JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez Á, Rodríguez CA, Ruíz A, Llombart A.

Clin Transl Oncol. 2017 May;19(5):616-624. doi: 10.1007/s12094-016-1571-4. Epub 2016 Nov 16. Review.

PMID:
27853985
7.

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.

Cinieri S, Chan A, Altundag K, Vandebroek A, Tubiana-Mathieu N, Barnadas A, Dodyk P, Lazzarelli S, Botha M, Rauch D, Villanova G, Coskun U.

Clin Breast Cancer. 2017 Apr;17(2):91-99.e1. doi: 10.1016/j.clbc.2016.06.014. Epub 2016 Jun 25.

PMID:
27756583
8.

Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.

Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruysscher D, Cesaretti JA, Barnett GC, Dunning AM, Dorling L, West CM, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Ramon Y Cajal T, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollà M, Díez O, Yarnold JR, Overgaard J, Bentzen SM, Alsner J; International Radiogenomics Consortium (RgC).

Radiother Oncol. 2016 Dec;121(3):431-439. doi: 10.1016/j.radonc.2016.06.017. Epub 2016 Jul 18.

PMID:
27443449
9.

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.

Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J, Calvo L, García-Asenjo JA, Palacios J, Chacon JI, Ruiz A, De la Haba-Rodriguez J, Segui-Palmer MA, Cirauqui B, Margeli M, Plazaola A, Barnadas A, Casas M, Caballero R, Carrasco E, Rojo F.

Oncologist. 2016 Jun;21(6):778. doi: 10.1634/theoncologist.2015-0312erratum. No abstract available.

10.

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.

Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M.

Clin Cancer Res. 2017 Feb 1;23(3):649-657. doi: 10.1158/1078-0432.CCR-16-0162. Epub 2016 Jun 14.

11.

Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.

Tibau A, Ocana A, Anguera G, Seruga B, Templeton AJ, Barnadas A, Amir E.

JAMA Oncol. 2016 Jun 1;2(6):744-50. doi: 10.1001/jamaoncol.2015.6479.

PMID:
26940233
12.

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.

Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J, Calvo L, García-Asenjo JA, Palacios J, Chacon JI, Ruiz A, De la Haba-Rodriguez J, Segui-Palmer MA, Cirauqui B, Margeli M, Plazaola A, Barnadas A, Casas M, Caballero R, Carrasco E, Rojo F.

Oncologist. 2016 Feb;21(2):150-5. doi: 10.1634/theoncologist.2015-0312. Epub 2016 Jan 19. Erratum in: Oncologist. 2016 Jun;21(6):778.

13.

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.

Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, Moran S, Heyn H, Sebio A, Barnadas A, Pommier Y, Esteller M.

Oncotarget. 2016 Jan 19;7(3):3084-97. doi: 10.18632/oncotarget.6413.

14.

CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma.

Pavón MA, Parreño M, Téllez-Gabriel M, León X, Arroyo-Solera I, López M, Céspedes MV, Casanova I, Gallardo A, López-Pousa A, Mangues MA, Quer M, Barnadas A, Mangues R.

Head Neck. 2016 Apr;38 Suppl 1:E1392-403. doi: 10.1002/hed.24232. Epub 2015 Oct 30.

PMID:
26516695
15.

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, Rodríguez-Lescure Á, Muñoz-Mateu M, González S, Margelí Vila M, Barnadas A, Ramos M, Del Barco Berron S, Jara C, Calvo L, Martínez-Jáñez N, Mendiola Fernández C, Rodríguez CA, Martínez de Dueñas E, Andrés R, Plazaola A, de la Haba-Rodríguez J, López-Vega JM, Adrover E, Ballesteros AI, Santaballa A, Sánchez-Rovira P, Baena-Cañada JM, Casas M, del Carmen Cámara M, Carrasco EM, Lluch A.

J Clin Oncol. 2015 Nov 10;33(32):3788-95. doi: 10.1200/JCO.2015.61.9510. Epub 2015 Sep 28.

PMID:
26416999
16.

Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.

Pavón MA, Arroyo-Solera I, Téllez-Gabriel M, León X, Virós D, López M, Gallardo A, Céspedes MV, Casanova I, López-Pousa A, Mangues MA, Quer M, Barnadas A, Mangues R.

Oncotarget. 2015 Oct 6;6(30):29016-33. doi: 10.18632/oncotarget.5032.

17.

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M.

Curr Cancer Drug Targets. 2016;16(5):415-28. Review.

PMID:
26278712
18.

Mammographic density and breast cancer in women from high risk families.

Ramón Y Cajal T, Chirivella I, Miranda J, Teule A, Izquierdo Á, Balmaña J, Sánchez-Heras AB, Llort G, Fisas D, Lope V, Hernández-Agudo E, Juan-Fita MJ, Tena I, Robles L, Guillén-Ponce C, Pérez-Segura P, Luque-Molina MS, Hernando-Polo S, Salinas M, Brunet J, Salas-Trejo MD, Barnadas A, Pollán M.

Breast Cancer Res. 2015 Jul 11;17:93. doi: 10.1186/s13058-015-0604-1.

19.

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J.

Eur J Cancer. 2015 Aug;51(12):1481-9. doi: 10.1016/j.ejca.2015.03.018. Epub 2015 Jun 11.

PMID:
26074397
20.

Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study.

de Gonzalo-Calvo D, López-Vilaró L, Nasarre L, Perez-Olabarria M, Vázquez T, Escuin D, Badimon L, Barnadas A, Lerma E, Llorente-Cortés V.

BMC Cancer. 2015 Jun 9;15:460. doi: 10.1186/s12885-015-1469-5.

Supplemental Content

Loading ...
Support Center